285 related articles for article (PubMed ID: 17308370)
21. Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia.
Wiernik PH; Baig MA; Lee SH; Dutcher JP; Paietta E; Racevskis J
Clin Adv Hematol Oncol; 2011 Mar; 9(3):242-8. PubMed ID: 21475132
[No Abstract] [Full Text] [Related]
22. Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells.
Kobayashi S; Sato K; Kobayashi A; Osawa Y; Nakamura Y; Kimura F
Ann Hematol; 2011 Mar; 90(3):367-8. PubMed ID: 20556391
[No Abstract] [Full Text] [Related]
23. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
24. Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57.
Kreuzer KA; le Coutre P
Haematologica; 2004 Aug; 89(8):ELT12. PubMed ID: 15339701
[No Abstract] [Full Text] [Related]
25. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
26. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease in chronic myeloid leukemia.
Löwenberg B
N Engl J Med; 2003 Oct; 349(15):1399-401. PubMed ID: 14534331
[No Abstract] [Full Text] [Related]
28. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
[No Abstract] [Full Text] [Related]
29. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
30. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
Zámecníkova A; Al Bahar S; Ramesh P
Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
[TBL] [Abstract][Full Text] [Related]
31. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
[No Abstract] [Full Text] [Related]
32. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
Breccia M; Santopietro M; Loglisci G; Stagno F; Cannella L; Carmosino I; Alimena G
Leuk Res; 2010 Aug; 34(8):e224-5. PubMed ID: 20356624
[No Abstract] [Full Text] [Related]
33. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
[TBL] [Abstract][Full Text] [Related]
34. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
35. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Westfall DE; Zhang L; Song S; Lee S
Arch Pathol Lab Med; 2008 Jun; 132(6):1021-5. PubMed ID: 18517263
[TBL] [Abstract][Full Text] [Related]
36. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
37. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
[TBL] [Abstract][Full Text] [Related]
38. Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib?
Kim AS; Goldstein SC; Luger S; Van Deerlin VM; Bagg A
Am J Clin Pathol; 2008 Apr; 129(4):639-48. PubMed ID: 18343792
[TBL] [Abstract][Full Text] [Related]
39. An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy.
Maeda T; Mutoh T; Muta H; Nakayama M; Nakajima Y; Ikuta T; Yasuda M; Etoh T; Shimizu K; Nakazaki Y; Hiroyama T; Somada S; Kurita R; Tani K; Shiratsuchi M; Nishimura J
J Am Geriatr Soc; 2004 Oct; 52(10):1783-4. PubMed ID: 15450069
[No Abstract] [Full Text] [Related]
40. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
